AI Terminal
ABIVAX
AGM Information • May 18, 2022
1063_rns_2022-05-18_83c289a6-0017-437e-a497-af84397f8325.html
AGM Information
Open in ViewerOpens in native device viewer
News Details
Corporate | 18 May 2022 18:00
ABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents
DGAP-News: ABIVAX / Key word(s): AGM/EGM
ABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents
18.05.2022 / 18:00
The issuer is solely responsible for the content of this announcement.
Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents
PARIS, France, May 18, 2022 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, informs its shareholders that its ordinary and extraordinary general meeting will be held on June 9, 2022, at 10:00 a.m. (CEST), at the offices of Dechert (Paris) LLP, located at 32 rue de Monceau in Paris (75008), France.
The Shareholders’ Meeting documents and information and the voting form have been made available to Shareholders under the terms and conditions specified by current French regulations, and are available on the Company’s website . All documents are exclusively available in French.
*****
About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.
Contacts
| Abivax Communications Regina Jehle [email protected] +33 6 24 50 69 63 |
Investors LifeSci Advisors Ligia Vela-Reid [email protected] +44 7413 825310 |
Press Relations & Investors Europe MC Services AG Anne Hennecke [email protected] +49 211 529 252 22 |
| Public Relations France Actifin Ghislaine Gasparetto [email protected] +33 6 21 10 49 24 |
Public Relations France Primatice Thomas Roborel de Climens [email protected] +33 6 78 12 97 95 |
Public Relations USA Rooney Partners LLC Jeanene Timberlake [email protected] +1 646 770 8858 |
18.05.2022 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de